Signal mining of breast cancer antibody-drug conjugates related interstitial lung disease adverse drug reaction
10.3969/j.issn.1673-9701.2025.32.015
- VernacularTitle:乳腺癌抗体偶联药物相关间质性肺病不良反应信号挖掘分析
- Author:
Min YANG
1
;
Datian FU
;
Zhuo ZHANG
Author Information
1. 海南省肿瘤医院肿瘤内科,海南海口 570312
- Publication Type:Journal Article
- Keywords:
Signal mining;
Antibody-drug conjugates;
Interstitial lung disease
- From:
China Modern Doctor
2025;63(32):62-66
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically analyze novel antibody-drug conjugates(ADCs)associated with breast cancer that cause interstitial lung disease(ILD),providing a reference for the safe clinical use of ADCs.Methods A total of 909 ILD adverse event reports Adverse event reports were collected,extracted from the US Food and Drug Administration Adverse Event Reporting System database.The correlation between trastuzumab deruxtecan(T-DXd),trastuzumab emtansine(T-DM1),and sacituzumab govitecan(SG)with ILD were evaluated using the reporting odds ratio(ROR)and proportional reporting ratio(PRR)methods from the disproportionality analysis.Descriptive analysis was performed on the main characteristics of ILD patients(gender,age,time of onset,and outcomes).Results Including 812 for T-DXd,84 for T-DM1,and 13 for SG.The ROR values were 15.97,2.21,and 0.41,respectively,and the PRR values were 15.33,2.19,and 0.41.T-DXd and T-DM1 showed significant correlations with ILD,with the risk signal strength of T-DXd being significantly higher than that of T-DM1.The median time to ILD onset for T-DXd,T-DM1,and SG was 76.0 days,66.0 days,and 53.5 days,respectively.The number of deaths caused by ILD was 265 cases,13 cases,and 1 case,respectively,with the first 180 days after initial administration being a critical monitoring period.Conclusion The risk of ILD induced by different ADC drugs exhibits significant heterogeneity.Clinicians must remain highly vigilant for ILD caused by these agents,emphasizing early diagnosis and treatment to reduce mortality.
